Neuromodulation as a Therapy for PTSD following Chronic TBI
Project Number5I01RX002705-05
Contact PI/Project LeaderWOLF, JOHN ALLEN
Awardee OrganizationPHILADELPHIA VA MEDICAL CENTER
Description
Abstract Text
Although PTSD is a frequent co-morbidity of traumatic brain injury in Veterans, the neurophysiological basis
underlying the contribution of TBI to PTSD remains unknown, and there are currently few effective treatments
available for this prevalent co-morbidity. A number of human and rodent studies have demonstrated that TBI
can exacerbate fear responses, and affect the ability to extinguish a conditioned fear response. Others have
demonstrated in PTSD models that there is a shift in the balance between limbic structures (prefrontal cortex,
the hippocampus and amygdala) after fear conditioning. Surprisingly, there have been few reports to date of
how the network neurophysiology underlying these behavioral changes are affected by TBI. A potential
treatment for PTSD using neuromodulation is in trials in Veterans, but we don’t have a clear understanding of
how TBI would affect this neuromodulation. There is no accepted theory or supporting data demonstrating how
the encoding/recall of fear learning and memory are disrupted by TBI, or how TBI affects the ability to extinguish
fear. Therefore, a critical need exists to determine the underlying mechanism of how TBI leads to alteration of
fear learning and extinction after traumatic brain injury. Without a deeper understanding of how TBI affects this
circuitry, rational design of neuromodulatory and other therapies targeting fear processing remains improbable.
The overall objective of the current application is to determine how the coding of fear in extended amygdalar
circuitry is affected following TBI, and whether neuromodulation can enable faster fear extinction. Our central
hypothesis is that TBI disrupts normal communication between the amygdala and other regions
underlying fear memory, which leads to overexpression of fear learning, generalization to other
situations, and an inability to extinguish learned fear. This hypothesis is based in part on predictions from
our preliminary data demonstrating that injured animals have increased time to extinguish fear, that neurons in
the limbic system have different firing properties and entrain to oscillations in a different manner following injury,
and others data demonstrating that neuromodulation in the amygdala can eliminate PTSD-like symptoms. In
order to test the above hypothesis, we will first determine the mechanism of TBI induced fear responses in rats
using simultaneous multi-site recordings and neuropathology. We believe axonal injury affects top down input
from the prefrontal cortex, as well as organizing input from the hippocampus (theta oscillations), leading to
heightened amygdalar fear responses and poor consolidation of extinction memory. For the first time, we will
also test neuromodulation as a treatment to restore normal balance in the extended amygdalar circuitry and
restore extinction of fear. We hypothesize that extinction of fear responses in the amygdala can be restored by
modulating the remaining prefrontal and/or hippocampal connections to the amygdala. In addition, we will utilize
a preclinical pig model of pure diffuse axonal injury to determine whether loss of connections between limbic
regions leads to changes in fear memory and an inability to extinguish fear. We believe inertial brain injury
induces diffuse axonal injury which disrupts connections between prefrontal cortex, hippocampus and the
amygdala, leading to an increase in fear expression and failure of extinction following TBI. Accomplishment of
these goals will provide the first detailed physiological analysis of the mechanisms of TBI induced PTSD-like
phenotypes across multiple diffuse TBI models. Furthermore, accomplishment of these aims will identify the
causal effects of electrical stimulation on these pathways and whether it restores function in rodent models,
leading to crucial mechanistic results that can be translated to preclinical and future clinical treatment for
comorbid TBI/PTSD. Identification of the neuronal network disruption underlying TBI associated PTSD will not
only advance our understanding of the interplay between these disorders, but allow for the development of
targeted treatments for this common co-morbidity in our Veterans.
Public Health Relevance Statement
Traumatic brain injury (TBI) is considered the “signature” injury of the recent US wartime conflicts, with
approximately 15% of warfighters experiencing single or multiple mild TBIs (mTBI). PTSD is a frequent
comorbidity in this population, with almost 35% of mTBI exposed Veterans reporting qualifying symptoms
associated with their service in theater. The presenting symptomatology of PTSD (i.e., emotion dysregulation
and cognitive deficits) may have an underlying basis in the biomechanical disruption by TBI of brain regions
underlying emotional processing and memory. This same disruption may interfere with effective treatment.
Animal models are necessary in order to unravel the effect of TBI on the brain circuitry underlying PTSD. We
will therefore utilize high density electrophysiology (recordings) and stimulation in awake behaving rats and
pigs to elucidate how TBI affects the circuitry underlying PTSD, the acquisition and extinction of PTSD-like
behavioral phenotypes, and to develop a new neuromodulatory treatment for this co-morbidity.
No Sub Projects information available for 5I01RX002705-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5I01RX002705-05
Patents
No Patents information available for 5I01RX002705-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5I01RX002705-05
Clinical Studies
No Clinical Studies information available for 5I01RX002705-05
News and More
Related News Releases
No news release information available for 5I01RX002705-05
History
No Historical information available for 5I01RX002705-05
Similar Projects
No Similar Projects information available for 5I01RX002705-05